Rate My Professor Glen Reid

Associate Professor Glen Reid is the Head of the Department of Pathology and Molecular Medicine at the University of Otago's Dunedin School of Medicine, within the Faculty of Medicine. He holds a PhD from the University of Göttingen, completed between 1997 and 2000, after studying Cell and Molecular Biology at the University of Canterbury from 1994 to 1995. His career trajectory includes serving as Senior Researcher at the Asbestos Diseases Research Institute, University of Sydney, from April 2009 to April 2018, where he conducted translational research on malignant pleural mesothelioma, contributing to biomarker identification and a phase I clinical trial of microRNA replacement therapy (NCT02369198). Prior to that, he worked on RNA interference at Genesis Research & Development Corporation in Auckland from August 2004 to April 2009. Since July 2018, Reid has been Associate Professor at the University of Otago, leading research initiatives in cancer pathology.

Reid's academic interests center on translational cancer research, including the emergence of drug-tolerant persister cells in lung cancer and melanoma, the role of microRNAs in mesothelioma biology, biomarker discovery, and nucleic acid-based cancer therapies. Current projects explore KRAS expression in drug tolerance, untranslated p53 mRNA in drug resistance, and strategies to inhibit adaptive mutability. He received a $195,892 research grant from the Cancer Society of New Zealand to investigate drug-tolerant cells during cancer treatment. Key publications include 'Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma' (The Lancet Oncology, 2017), 'Therapeutic potential of synthetic microRNA mimics based on the miR-15/107 consensus sequence' (Cancer Gene Therapy, 2025), 'MicroRNA mimics based on the miR-15/107 consensus sequence sensitise NSCLC cells to targeted therapy' (International Journal of Molecular Sciences, 2026), 'Asbestos-Related lung Cancer: An underappreciated oncological issue' (2024), and 'Inhibition of YB-1 phosphorylation enhances cisplatin activity and disrupts cell division in pleural mesothelioma' (British Journal of Cancer, 2025). His research has garnered over 12,000 citations, influencing advancements in mesothelioma diagnostics and therapies.